Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...
Possibly the most absurd truth of modern computing is that, as far as the technology has evolved, we're fundamentally still doing the exact same thing we were doing decades ago: twiddling bits. The ...
Givaudan has a strong competitive moat, solid profitability, and a healthy balance sheet. It also finally appears reasonably ...
On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
Enterprises today are equipped with a vast array of tools and technologies. The opportunity lies in bringing these ...
Zacks Investment Research on MSN
MongoDB vs. Oracle: Which Database Stock Has the Brighter Outlook?
MongoDB MDB and Oracle ORCL are capitalising on the intersection of cloud migration and artificial intelligence to drive ...
Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA ...
BAE Systems (12 Nov) and Rolls-Royce (13 Nov) earnings preview: Both significantly outperform the FTSE 100 year-to-date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback